Also debuts TMR'09 campaign
IRVINE, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a global leader of innovative therapies for ischemic cardiac disease and the market leader of surgical products for transmyocardial revascularization (TMR), sponsored an educational symposium yesterday in conjunction with the 20th Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.
The symposium, titled "New Horizons in Cardiac Regenerative Medicine: Advancements in Revascularization & Stem Cell Therapy," was attended by over 120 cardiology healthcare practitioners. The Program Chair was Warren Sherman, MD, Director of Cardiac Cell Based Endovascular Therapies, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center. Presenters included: Emerson Perin, MD, PhD, Director, New Interventional Cardiovascular Technology, Texas Heart Institute; Marvin Slepian, MD, Director of Interventional Cardiology, University of Arizona, Sarver Heart Center; and Keith Allen, Cardiothoracic Surgeon, Mid America Heart and Thoracic surgeons, Kansas City, MO.
"The program was designed to provide an update to clinicians on the recent developments with advanced cardiovascular revascularization and regenerative therapies, with a focus on patients suffering from ischemic cardiac disease," Dr. Sherman stated. "TCT attendees are eager to learn about rapidly evolving therapies, as well as the latest information on optimizing outcomes with available tools and techniques, including TMR as a sole therapy and adjunctive to bypass surgery."
Dr. Allen emphasized to the cardiologists in attendance, "Surgeons are
innovating with Cardiogenesis to provide TMR with minimally invasive
approaches, including surgical robotic delivery." He also discussed the
early clinical experience with the PHOENIX combination delivery system
being collected from c
|SOURCE Cardiogenesis Corporation|
Copyright©2008 PR Newswire.
All rights reserved